Bromhexine-containing
cough and cold medicines, mostly
Schedule 2, have been identified
by the Therapeutic Goods
Administration (TGA) as posing a
risk of allergy and skin reactions,
in the latest TGA Medicines Safety
Update.
Lercanidipine and Marcain Spinal
0.5% Heavy also received mentions
with alerts for health professionals.
In addition, the TGA has
released its latest list of registered
complementary medicines that
have been evaluated for safety,
quality and efficacy.
Go to www.tga.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jun 16
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.